Share This Page
ORTHO-NOVUM 1/50 28 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ortho-novum 1/50 28, and when can generic versions of Ortho-novum 1/50 28 launch?
Ortho-novum 1/50 28 is a drug marketed by Ortho Mcneil Janssen and is included in one NDA.
The generic ingredient in ORTHO-NOVUM 1/50 28 is mestranol; norethindrone. There are eleven drug master file entries for this compound. Additional details are available on the mestranol; norethindrone profile page.
US Patents and Regulatory Information for ORTHO-NOVUM 1/50 28
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ortho Mcneil Janssen | ORTHO-NOVUM 1/50 28 | mestranol; norethindrone | TABLET;ORAL-28 | 016709-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Ortho-Novum 1/50 28 (ethinyl estradiol/norethindrone acetate) investment scenario and fundamentals analysis
Executive summary: Ortho-Novum 1/50 28 is a combined oral contraceptive (COC) product (ethinyl estradiol 0.035 mg and norethindrone acetate 1 mg) in a 28-day regimen. Because this is an established, small-molecule, long-commercialized COC category, the investment profile is driven by (i) generic and authorized generic penetration, (ii) payer and formulary dynamics for women’s health, and (iii) supply chain execution and lifecycle management (line extensions, NDC-level loyalty, and inventory control). A returns case depends on protecting differentiated “brand-like” economics through contracting, rebates, and product-level availability rather than on durable exclusivity.
Critical limitation: No complete, source-backed dataset (FDA label/NDC mapping, Orange Book listings, patent numbers, listed exclusivities, and FDA approval history for the specific “Ortho-Novum 1/50 28” SKU) is provided in the prompt. Without verifiable product identifiers and patent/regulatory records, a patent estate, litigation, generic entry risk, and exclusivity timeline cannot be stated accurately. Accordingly, the only investable fundamentals that can be grounded from first principles at this time are category-level drivers and what they imply for valuation under standard pharma commercialization logic.
What drives investment returns for Ortho-Novum 1/50 28 branded vs generic COC competition?
Featured snippet answer: Returns are primarily determined by how quickly true generics and authorized generics compress net price, plus how well the brand maintains formulary placement and pharmacy channel throughput.
COC category economics: the three levers
-
Net price compression
- COCs with long histories typically face multi-wave erosion as generics gain share and authorized generics reduce wholesale-to-retail arbitrage.
- Net price is rebate- and contract-driven. In women’s health, channel strategy and payer tiers often matter as much as WAC.
-
Volume stability
- COCs have repeat-purchase behavior and patient persistence effects, which can slow share loss even after generics enter.
- Interruption risk rises with manufacturing constraints and distribution issues because substitution is easy at the class level.
-
Formulary and PBM mechanics
- If a brand remains preferred within a formulary tier, net price may hold longer despite generic entry.
- If a brand is non-preferred, volume typically shifts quickly to generics, and marketing spend must increase to hold shelf position, hurting margin.
What that means for Ortho-Novum 1/50 28
- The product’s attractiveness to investors is less about exclusivity and more about channel resilience: pharmacy fill rates, backorder avoidance, and contracting discipline that caps rebate escalation.
How strong is the patent estate for Ortho-Novum 1/50 28 and what patents protect it?
Featured snippet answer: No source-backed patent estate for the specific “Ortho-Novum 1/50 28” SKU can be provided from the prompt. In COC portfolios, patents often shift over time from active ingredient composition and methods to formulations, dosage regimens, and manufacturing, but exact coverage must be confirmed against the Orange Book for the product.
Typical patent layers seen in COC brands
- Active ingredient composition claims (ethinyl estradiol + norethindrone acetate compositions)
- Dosage form and regimen claims (28-day cycle structure and tablet composition)
- Manufacturing/process claims (granulation, tablet press parameters, or stability-driven processing)
- Method-of-use claims (contraception and cycle control)
- Life-cycle extensions (e.g., alternative release or stability improvements)
Investment implication when patent data is not established
- Without validated patent term and exclusivity status for this exact NDC, any “durability” forecast is structurally unreliable.
- Under standard market practice, most investors treat mature COCs as non-exclusivity-driven businesses unless a documented regulatory or patent barrier exists.
When does Ortho-Novum 1/50 28 lose exclusivity and how soon do generics typically enter?
Featured snippet answer: For mature COC actives, generic competition usually arrives long before investors should underwrite meaningful remaining exclusivity. For this specific product, timing cannot be stated without verified FDA exclusivity and Orange Book records.
Investor-relevant timing frameworks for COCs
- Application pathway to generic entry: typically ANDA for an equivalent COC.
- Settlement dynamics: where patent challenges occur, entry timing can shift by settlements or court outcomes.
- Exclusivity types: 5-year exclusivity for certain NDA milestones can apply in new chemical entity contexts, but this category generally behaves like an “older” product class.
What to underwrite instead of exclusivity
- Shelf ownership: whether the brand has maintained pharmacy contracts that preserve share.
- NDC-level supply: whether the product stays available without intermittent shortages that accelerate switching.
What is the Orange Book status of Ortho-Novum 1/50 28?
Featured snippet answer: Orange Book status for “Ortho-Novum 1/50 28” cannot be verified from the prompt. Orange Book listings are NDC-specific, and the product string alone is not enough to map to the correct FDA record set.
Why NDC mapping matters
- Multi-strength, multi-manufacturer, or label variations can create multiple Orange Book entries.
- Exclusivity and patent expiration must be read at the NDA/NDC granularity.
What patent litigation affects Ortho-Novum 1/50 28 and what are the Paragraph IV risks?
Featured snippet answer: No litigation docket or Paragraph IV history for this specific product can be stated from the prompt.
How litigation affects COC economics when it exists
- A Paragraph IV win shifts risk toward earlier generic entry.
- Settlements can create “launch calendars” that dominate the brand’s remaining unit economics.
- If litigation is absent or resolved, the business behaves like a pure commercial competition story.
Investment implication
- For mature COCs, litigation-driven upside is usually limited unless a specific late-stage barrier exists for the exact NDC.
How does Ortho-Novum 1/50 28 compare with other ethinyl estradiol/norethindrone acetate 28-day COCs on price and share?
Featured snippet answer: Ortho-Novum 1/50 28 competes primarily on net price, formulary preference, and persistence, not on clinical differentiation, because COCs in the same dose family are typically therapeutically substitutable.
Comparability factors
- Dose equivalence within the same active strength class
- 28-day regimen labeling conventions
- Tablet design and adherence aids (if any in the label)
- Channel strategy (pharmacy distribution, copay programs, and contract rebates)
What to model
- Market share response as a function of net price spread versus generics.
- Sensitivity to PBM preferencing and switching friction (90-day supply fills vs monthly).
What generic entry risks exist for Ortho-Novum 1/50 28 and how does an ANDA launch change unit economics?
Featured snippet answer: Generic entry compresses margins mainly through net price and rebate re-optimization, with volume effects depending on formulary positioning and supply continuity.
Mechanics of margin compression
- WAC-to-NET spread narrows as PBMs steer to low-price generics.
- Rebate rates often rise if the brand fights to stay preferred.
- Gross margin declines with promotional intensity and higher customer acquisition cost.
What to stress in diligence
- Contract structures: share-of-voice incentives, bid-rotation terms, and rebate triggers tied to competitor positioning.
- Inventory and production scheduling: COCs have low differentiation and fast substitution, so stockouts can cause permanent share loss.
Which companies manufacture or sell Ortho-Novum 1/50 28 and how does it affect competitive leverage?
Featured snippet answer: Supplier/manufacturer concentration drives continuity risk and wholesale availability, but company mapping requires verified NDC-specific labeling data.
Diligence priorities
- Manufacturer and site-of-manufacture stability (FDA inspection outcomes can affect supply).
- Distributor performance and fill-rate history.
- Authorized generic presence (if any) that can blur differentiation and accelerate margin erosion.
What are the commercialization fundamentals for Ortho-Novum 1/50 28 (sales durability, channel, and margin drivers)?
Featured snippet answer: The sales base is typically durable due to repeat use, but profitability depends on maintaining preferred status and preventing supply disruptions.
Key fundamentals to underwrite
- Net sales durability
- Watch for NDC-level cannibalization by lower-priced equivalents.
- Unit persistence
- COCs can hold usage across switching events if access remains consistent.
- COGS and gross margin
- Packaging and tablet manufacturing costs are relatively stable; margin variability is mostly rebate/promotional and supply-chain disruptions.
- OPEX discipline
- In mature COCs, brand-funded differentiation is usually limited. Spend that does not preserve formulary preference does not translate into lasting share.
Investment scenarios: base case vs downside vs upside for Ortho-Novum 1/50 28
Base case (most likely for mature COCs)
- Assumption set: ongoing generic presence, slow erosion of net price, moderate share retention.
- Expected outcome: stable volumes, margin pressure contained by contracting discipline; earnings growth driven by cost control and supply reliability.
Downside case
- Assumption set: accelerated PBM preferencing shift to generics or authorized generics; rebate escalation; intermittent supply constraints.
- Expected outcome: sharp net price decline and volume loss; operating leverage turns negative.
Upside case
- Assumption set: the product remains preferred longer than peers via managed-care contracts; competitive set stays fragmented; no supply interruption.
- Expected outcome: slower margin compression and better-than-category retention; cash flow stability supports valuation.
Key Takeaways
- Ortho-Novum 1/50 28 investment returns are driven by commercial execution more than by exclusivity, consistent with mature COC market structure.
- Without NDC-mapped Orange Book and FDA record support, patent expiration, exclusivity, and litigation timelines cannot be stated for this SKU.
- The investable diligence focus is: net price mechanics (rebates/contracts), formulary preference durability, supply continuity, and authorized-generic dynamics.
- Valuation should be modeled as a channel and margin business under multiple generic/authorized-generic scenarios rather than as an IP-driven franchise unless the Orange Book confirms a late-stage barrier.
FAQs
- How does authorized generic competition typically affect net price for branded ethinyl estradiol/norethindrone acetate products?
- What formulary mechanisms (tiering, step edits, prior authorization) most influence COC switching speed after generic launches?
- How do supply disruptions for oral contraceptives change long-term share retention versus temporary backorder effects?
- What metrics best predict rebate escalation risk in mature women’s health categories (payer mix, channel inventory, bid rotation)?
- How should investors model COC margin sensitivity to WAC changes when net price is primarily contract-driven?
References (APA)
No sources are cited because the prompt does not include verifiable FDA/NDC mappings, Orange Book listings, or litigation records for Ortho-Novum 1/50 28.
More… ↓
